Ftorafur is an antimetabolite pyrimidine analog that exhibits anticancer chemotherapeutic activity. Ftorafur is a prodrug of 5-fluorouracil that inhibits thymidylate synthase, preventing thymidine synthesis. Ftorafur is typically clinically co-administered with other chemotherapeutics to decrease its peripheral cytotoxicity.
| Cas No. | 17902-23-7 |
|---|---|
| Purity | ≥98% |
| Formula | C8H9FN2O3 |
| Formula Wt. | 200.17 |
| Chemical Name | 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)- pyrimidinedione |
| IUPAC Name | 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione |
| Synonym | Tegafur; Citofur; Furafluor; 5-Fluoro-1-(tetrahydro-2-furyl)uracil |
| Melting Point | 164-169°C |
| Solubility | Soluble in hot water, ethanol, methanol,or DMSO. |
| Appearance | White Crystal Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | F7657 MSDS PDF |
|---|---|
| Info Sheet | F7657 Info Sheet PDF |
Fukushima M. Antitumor activity and function of S-1, a new oral tegafur-based formulation. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:19-26. PMID: 16897968.
Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. PMID: 12724731.
Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol. 2000 Sep;1(2):137-64. PMID: 11467334.
